A cross-section of biopharma experts deliberated at a recent summit what’s holding back foreign sponsor interest in clinical trials in India and sought to address some of the “hurdles” and “perceptions” that are currently weighing things down.
Peter Ronco, head of global development, Janssen Research and Development, Johnson & Johnson, emphasized the need to “embed” many of the changes and innovations that the Indian regulatory system was forced to adopt
“Great innovations that we need to maintain are things like how do we optimize the speed of review of regulatory packages, which is such a critical part of having a competitive advantage in terms of how India is competing with other countries around the world for clinical trial populations,” Ronco said at the USA-India Chamber of Commerce (USAIC) annual Biopharma and Healthcare Summit